BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19995332)

  • 41. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
    Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
    Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
    Erickson DA; Hollfelder S; Tenge J; Gohdes M; Burkhardt JJ; Krieter PA
    Drug Metab Dispos; 2007 Dec; 35(12):2232-41. PubMed ID: 17881661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
    Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
    Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
    Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
    Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro metabolism of l-corydalmine, a potent analgesic drug, in human, cynomolgus monkey, beagle dog, rat and mouse liver microsomes.
    Tang X; Di X; Zhong Z; Xie Q; Chen Y; Wang F; Ling Z; Xu P; Zhao K; Wang Z; Liu L; Liu X
    J Pharm Biomed Anal; 2016 Sep; 128():98-105. PubMed ID: 27239758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes.
    Riley RJ; Roberts P; Kitteringham NR; Park BK
    Biochem Pharmacol; 1990 Jun; 39(12):1951-8. PubMed ID: 2353936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food.
    Niwa T; Murayama N; Umeyama H; Shimizu M; Yamazaki H
    Drug Metab Lett; 2011 Aug; 5(3):216-9. PubMed ID: 21679153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
    Corchero J; Granvil CP; Akiyama TE; Hayhurst GP; Pimprale S; Feigenbaum L; Idle JR; Gonzalez FJ
    Mol Pharmacol; 2001 Dec; 60(6):1260-7. PubMed ID: 11723233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue.
    Ning M; Duarte JD; Rubin LH; Jeong H
    Clin Pharmacol Ther; 2018 Nov; 104(5):974-982. PubMed ID: 29349771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
    Bijl MJ; Visser LE; Hofman A; Vulto AG; van Gelder T; Stricker BH; van Schaik RH
    Br J Clin Pharmacol; 2008 Apr; 65(4):558-64. PubMed ID: 18070221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imipramine: a model drug for P450 research.
    Brøsen K; Skjelbo E; Nielsen KK
    Methods Enzymol; 1996; 272():177-86. PubMed ID: 8791776
    [No Abstract]   [Full Text] [Related]  

  • 52. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
    Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
    J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
    Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
    Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
    Gibbs JP; Hyland R; Youdim K
    Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2D plays a major role in berberine metabolism in liver of mice and humans.
    Guo Y; Li F; Ma X; Cheng X; Zhou H; Klaassen CD
    Xenobiotica; 2011 Nov; 41(11):996-1005. PubMed ID: 21787170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
    Cruz HG; Hay JL; Hoever P; Alessi F; te Beek ET; van Gerven JM; Dingemanse J
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1257-68. PubMed ID: 24880753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
    Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
    Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
    Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
    Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.